Overall impact
C (54)

Commentary

Praxis is an average overall performer. With a 'C' rating of 54.3 for overall impact (50th percentile compared to all companies), Praxis ranks 546th out of 650 industry peers, behind Curium Pharma, Allena Pharmaceuticals, Pluristem Therapeutics and 542 others, and ahead of Viking Therapeutics, Aldeyra Therapeutics, Aptose Biosciences and 101 others. On top material causes for Praxis's industry (Biotechnology), Praxis performs well in Accountable Institutions (95.2 score), Accountable Institutions (95.2), Access to Affordable Healthcare (95.4) and 10 other causes where it received an 'A' score and performs poorly in Reduced Waste (10.7 score), Sustainable Use of Water (0.6), Improved Mental Health (6.4) and 11 other causes where it received a 'D' or 'F' score.
Impact
Cause PRAX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2015
Employees
82
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Massachusetts, United States
Share classes
PRAX
Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Material causes
Ethos considers the following causes material for Praxis, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.